Phase 2A Open Label Safety Study of Fovista (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2016
At a glance
- Drugs Pegpleranib (Primary) ; Vascular endothelial growth factors inhibitors
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors OphthoTech Corporation
- 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 05 Aug 2015 According to an Ophthotech media release, interim data from this trial is expected by the end of 2015.
- 22 May 2015 Planned End Date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrials.gov